EFFICACY AND SAFETY OF BOSUTINIB IN PATIENTS WITH RESISTANT CHRONIC MYELOID LEUKAEMIA OR INTOLERANT TO ATLEAST 3 INHIBITORS OF PRIOR TYROSINE KINASE

被引：0

作者：

Valentin, Garcia-Gutierrez ^{[1
]}

Dragana, Milojkovic ^{[2
]}

Luis Felipe, Casado ^{[3
]}

Simone, Claudiani ^{[2
]}

Antonio, Jimenez-Velasco ^{[4
]}

Maria Luisa, Marten-Mateos ^{[5
]}

Concepcion, Boque ^{[6
]}

Alejandra, Martinez-Trillo ^{[7
]}

Isabel, Mata ^{[8
]}

Payer Angel, Ramirez ^{[9
]}

Alberto, Alvarez-Larran ^{[10
]}

Elena, Amutio ^{[11
]}

Garcia Abelardo, Barez ^{[12
]}

Guiomar, Bautista ^{[13
]}

Barela Sabela, Bobillo ^{[14
]}

Ruiz Beatriz, Cuevas ^{[15
]}

Pilar, Giraldo ^{[16
]}

Jose Manuel, Puerta ^{[17
]}

Maria Jose, Ramirez ^{[18
]}

Gerosa Silvana, Saavedra ^{[19
]}

Sandra, Valencia ^{[20
]}

Rivas Fernando, Ortega ^{[21
]}

Mas Ana, Rossel ^{[22
]}

Fabio, Ruiz ^{[23
]}

Juan Luis, Steegmann ^{[24
,25
]}

机构：

[1] Hosp Univ Ramon y Cajal, Serv Hematol & Hemoterapia, Madrid, Spain

[2] Imperial Coll, Hammersmith Hosp, London, England

[3] Hosp Virgen de la Salud, Toledo, Spain

[4] 8Hosp Univ Carlos Haya, Malaga, Spain

[5] Hosp San Pedro de Alcantara, Serv Hematol, Caceres, Spain

[6] Insitute Cotele Oncol, Barcelona, Spain

[7] Hosp Clin Barcelona, Serv Hematol, Barcelona, Spain

[8] Hosp Costa Sol, Malaga, Spain

[9] Hosp Univ Cent Asturias, Oviedo, Spain

[10] Hosp del Mar, Serv Hematol, Barcelona, Spain

[11] Hosp Cruces, Vizcaya, Spain

[12] Hosp Nuestra Senora Sonsoles, Serv Hematol, Avila, Spain

[13] Hosp Univ Puerta de Hierro, Serv Hematol, Majadahonda, Spain

[14] Hosp Valle De Hebron, Barcelona, Spain

[15] Hosp Univ Burgos, Burgos, Spain

[16] Miguel Servet Univ Hosp, Haematol, Zaragoza, Spain

[17] Hosp Univ Virgen de las Nieves, Unidad Gest Clin Hematol & Hemoterapia, Granada, Spain

[18] Hosp Jerez Frontera, Serv Hematol, Cadiz, Spain

[19] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[20] Hosp Segovia, Serv Hematol, Segovia, Spain

[21] Hosp Palencia, Hematol 29Serv, Palencia, Spain

[22] 33Hosp Virgen de la Victoria, Malaga, Spain

[23] Hosp Univ Ramon y Cajal, Serv Hematol & Hemoterapia, Madrid, Spain

[24] Hosp Princesa, Hematol, Madrid, Spain

[25] Hosp Princesa, IIS IP, Madrid, Spain

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CO-126

引用

页码：79 / 80

页数：2

共 50 条

[21] Chakalaka-induced vasodilatation in patients with chronic myeloid leukaemia on tyrosine kinase inhibitors
Coetzee, Marius J.
Louw, Vernon J.
Gartrell, Kevin
Viljoen, Chris D.
SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2009, 99 (12): : 870 - 871
[22] Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data
Breccia, Massimo
Tiribelli, Mario
Alimena, Giuliana
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 84 (01) : 93 - 100
[23] Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
Wieczorek, Agnieszka
Uharek, Lutz
BIOMARKER INSIGHTS, 2015, 10 : 49 - 54
[24] Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
Cortes, J.
Digumarti, R.
Parikh, P. M.
Wetzler, M.
Lipton, J. H.
Hochhaus, A.
Craig, A. R.
Benichou, A. -C.
Nicolini, F. E.
Kantarjian, H. M.
AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (05) : 350 - 354
[25] Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Gianantonio Rosti
Fausto Castagnetti
Gabriele Gugliotta
Michele Baccarani
Nature Reviews Clinical Oncology, 2017, 14 : 141 - 154
[26] Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease
Leong, Darryl
Aghel, Nazanin
Hillis, Christopher
Siegal, Deborah
Karampatos, Sarah
Rangarajan, Sumathy
Pond, Gregory
Seow, Hsien
HEART, 2021, 107 (08) : 667 - 673
[27] Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Rosti, Gianantonio
Castagnetti, Fausto
Gugliotta, Gabriele
Baccarani, Michele
NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (03) : 141 - 154
[28] TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA: A SYSTEMATIC REVIEW
Ferdinand, R.
Mitchell, S.
Batson, S.
Tumur, I.
HAEMATOLOGICA, 2012, 97 : 533 - 533
[29] Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs.
Ibrahim, Amr R.
Bua, Marco
Khorshad, Jamshid S.
Milojkovic, Dragana
Eliasson, Lina
Szydlo, Richard
Foroni, Letizia
Reid, Alistair
de Lavallade, Hugues
Rezvani, Katayoun
Goldman, John M.
Apperley, Jane
Marin, David
BLOOD, 2010, 116 (21) : 936 - 936
[30] Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy
Massaro, Fulvio
Colafigli, Gioia
Molica, Matteo
Breccia, Massimo
EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (04) : 301 - 306

← 1 2 3 4 5 →